Association of Complement Factor H and LOC387715 Genotypes with Response of Exudative Age-Related Macular Degeneration to Intravitreal Bevacizumab

Brantley, Milam A.; Fang, Amy; King, Jennifer; Tewari, Asheesh; Kymes, Steven M.; Shiels, Alan

doi:10.1016/j.ophtha.2007.09.008

Cited by 192 publications

(153 citation statements)

References 41 publications

Supporting

Mentioning

133

Contrasting

Unclassified

Order By: Relevance

“…Visual acuity at presentation was the worst in the lower risk CFH TT group (P ¼ 0.12), consistent with our previous studies. 12,13 Mean post-PDT VA declined 2.2 lines for both the CFH CC and TC genotypes, but fell 4.0 lines for the TT genotype. After correcting for age, pre-PDT VA, and lesion type, we found this difference in post-PDT VA to be significant (P ¼ 0.05).…”

Section: Discussionmentioning

confidence: 97%

“…[2][3][4][5] The presence of the CFH Y402H polymorphism correlates with both exudative 6,7 and advanced atrophic 8 AMD, as well as AMD progression, 9 but limited data are available evaluating AMD phenotypes or response to treatment with regard to CFH genotype. [10][11][12][13] The association of AMD with two distinct polymorphisms within chromosome 10q26 has identified this region as a second major locus contributing to AMD pathogenesis. The non-synonymous SNP rs10490924, predicted to result in a coding variation (A69S) within the hypothetical gene LOC387715, was found to confer an increased risk for development of AMD, 14,15 and this locus has been renamed ARMS2 (age-related maculopathy susceptibility gene 2).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Association of complement factor H and LOC387715 genotypes with response of exudative age-related macular degeneration to photodynamic therapy

Brantley

Edelstein

King

et al. 2008

Eye

View full text Add to dashboard Cite

Aim To determine whether there is an association between complement factor H (CFH) or LOC387715 genotypes and response to treatment with photodynamic therapy (PDT) for exudative age-related macular degeneration (AMD). Methods Sixty-nine patients being treated for neovascular AMD with PDT were genotyped for the CFH Y402H and LOC387715 A69S polymorphisms by allele-specific digestion of PCR products. AMD phenotypes were characterized by clinical examination, fundus photography, and fluorescein angiography. Results Adjusting for age, pre-PDT visual acuity (VA), and lesion type, mean VA after PDT was significantly worse for the CFH TT genotype than for the TC or CC genotypes (P ¼ 0.05). Post-PDT VA was significantly worse for the CFH TT genotype in the subgroup of patients with predominantly classic choroidal neovascular lesions (P ¼ 0.04), but not for the patients with occult lesions (P ¼ 0.22). For the LOC387715 A69S variant, there was no significant difference among the genotypes in response to PDT therapy. Conclusions The CFH Y402H variant was associated with a response to PDT treatment in this study. Patients with the CFH TT genotype fared significantly worse with PDT than did those with the CFH TC and CC genotypes, suggesting a potential relationship between CFH genotype and response to PDT.

show abstract

Section: Discussionmentioning

confidence: 97%

Section: Introductionmentioning

confidence: 99%

Association of complement factor H and LOC387715 genotypes with response of exudative age-related macular degeneration to photodynamic therapy

Brantley

Edelstein

King

et al. 2008

Eye

View full text Add to dashboard Cite

show abstract

“…Características genéticas, demográficas e clínicas têm sido associadas na literatura com a resposta à terapia antiangiogênica para a DMRIn 6,7,8 . Aspectos morfológicos da TCO também foram propostos como base para uma nova classificação da doença 9 .…”

Section: Discussionunclassified

Tomographic findings predictive of the anatomic response to ranibizumab in age-related macular degeneration

Evangelista¹,

Honório²,

Leite³

et al. 2018

eOftalmo

View full text Add to dashboard Cite

Como citar: Evangelista IWQ; Honório CRC; Leite EP; Eulálio TC. Aspectos tomográficos preditivos da resposta anatômica ao ranibizumabe na degeneração macular relacionada à idade. eOftalmo. 2018: 4(2): 80-85. http://dx.doi.org/10.17545/eoftalmo/2018.0014Objetivo: Este estudo objetivou verificar se características morfológicas à tomografia de coerência óptica de domínio espectral afetam os resultados anatômicos na degeneração macular relacionada à idade neovascular tratada com ranibizumabe. Métodos: Avaliou-se a presença de fluido intrarretiniano, de fluido sub-retiniano, de fluido intrarretiniano associado a fluido sub-retiniano, além de descolamento do epitélio pigmentar da retina, antes do tratamento, e a associação dessas alterações com a ausência de fluido retiniano, após o tratamento. Foram incluídos 22 olhos virgens de tratamento e submetidos a injeções mensais de ranibizumabe. Resultados: Inicialmente, 22,7% dos olhos apresentavam apenas fluido intrarretiniano (grupo 1), 27,2%, apenas fluido sub-retiniano (grupo 2) e 45,4%, combinação de fluidos intrarretiniano e sub-retiniano (grupo 3). Com o tratamento, os percentuais de olhos que se apresentaram sem fluido foram 66,6, 60,0 e 33,3% para os grupos 1, 2 e 3, respectivamente. Nenhum dos olhos com descolamento do epitélio pigmentar associado às alterações iniciais se apresentou sem fluido após o tratamento. Conclusão: Olhos que apresentavam descolamento do epitélio pigmentar inicialmente exibiram a pior resposta anatômica ao tratamento com ranibizumabe. Olhos com a associação de fluidos intrarretiniano e sub-retiniano responderam pior ao tratamento do que aqueles com fluido sub-retiniano ou fluido intrarretiniano como alteração isolada. ABSTRACTObjective: This study aimed to assess whether morphological features observed on spectral domain optical coherence tomography affect anatomical results in patients with neovascular age-related macular degeneration treated with ranibizumab. Methods: Before treatment, we assessed the presence of intraretinal fluid, subretinal fluid, an association between both, and retinal pigment epithelial detachment. After treatment, we assessed the association between these changes and the absence of retinal fluid. Twenty-two virgin eyes were included and underwent monthly injections of ranibizumab. Results: Before treatment, 22.7% of the eyes presented with intraretinal fluid only (group 1), 27.2% exhibited subretinal fluid only (group 2), and 45.4% had a combination of both (group 3). After treatment, 66.6%, 60.0%, and 33.3% of the eyes in groups 1, 2, and 3, respectively, presented no fluid, and none of the eyes with pigment epithelial detachment associated with the initial changes presented no fluid. Conclusion: Eyes with retinal pigment epithelial detachment before treatment had the worst anatomical response to ranibizumab treatment. Eyes with a combination of both intraretinal and subretinal fluids had a worse response to treatment than those with intraretinal or subretinal fluid alone.Palavras-chave: Degeneração Macular; Rani...

show abstract

“…In the light of the recent reports, it can be considered that the potential risk factors for non-responsiveness to anti-VEGF agent in the treatment of n-AMD are an initial lesion with subfoveal fibrosis or atrophy in retina pigment epithelium and photoreceptors, lesion in large size, type 1 choroidal neovascularization, serous pigment epithelium detachment (PED), haemorrhagic PED, fibrovascular PED, polypoidal choroidal vasculopathy, foveal scarring and vitreomacular traction, outer retinal tubulation, cystoid degeneration in outer retina, genetic disposition or an anti-VEGF resistance [Table 1, 13-22]. Table 1: The possible risk factors for non-responsiveness to anti-VEGF agents in the patients with nAMD [6][7][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22].…”

Section: Editorialmentioning

confidence: 99%

The non-Responsiveness to Anti-Vascular Endothelial Growth Factor Agents in the Treatment of Neovascularage-Related Macular Degeneration

Turgut¹

2017

AOVS

View full text Add to dashboard Cite

In this editorial, the definition and potential risk factors of the non-responsiveness to the intravitreal applications of anti-vascular endothelial growth factors in the patients with neovascular age-related macular degeneration were summarized. To know the potential risk factors for the non-responsiveness to these agents may prevent unnecessary treatment interventions and unrealistic patient expectations.

show abstract

Association of Complement Factor H and LOC387715 Genotypes with Response of Exudative Age-Related Macular Degeneration to Intravitreal Bevacizumab

Cited by 192 publications

References 41 publications

Association of complement factor H and LOC387715 genotypes with response of exudative age-related macular degeneration to photodynamic therapy

Association of complement factor H and LOC387715 genotypes with response of exudative age-related macular degeneration to photodynamic therapy

Tomographic findings predictive of the anatomic response to ranibizumab in age-related macular degeneration

The non-Responsiveness to Anti-Vascular Endothelial Growth Factor Agents in the Treatment of Neovascularage-Related Macular Degeneration

Contact Info

Product

Resources

About